Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (61-70 of 288) with videos related to

Pageof 29
Sort By:
Clinical Lung Cancer|April 20, 2012
Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical centerJeffrey T Yorio, Jingsheng Yan, Yang Xie, et al.
Clinical Lung Cancer|December 31, 2018
Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesElizabeth McGehee, David E Gerber, Joan Reisch, et al.
Translational Lung Cancer Research|September 12, 2022
Circulating mitochondrial DNA as a biomarker for lung cancer screeningMitchell S von Itzstein, David E Gerber, John D Minna
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Impact of NCI-mandated scientific review on protocol development and contentNing Ning, Jingsheng Yan, Xian-Jin Xie, et al.
Journal of Radiotherapy in Practice|September 28, 2011
Intracranial hemorrhage during GliaSite RTS manipulation in an anticoagulated patientDavid E Gerber, Stuart A Grossman, Timothy A Chan, et al.
Plos One|January 4, 2013
How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experienceEvelyn O Taiwo, Jeffrey T Yorio, Jingsheng Yan, et al.
JAMA Oncology|June 5, 2016
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment OptionsSaad A Khan, Sandi L Pruitt, Lei Xuan, et al.
JTO Clinical and Research Reports|March 17, 2022
Systemic and Intracranial Efficacy of Osimertinib in <i>EGFR</i> L747P-Mutant NSCLC: Case ReportDavid E Gerber, Melissa Mayer, Jeffrey Gagan, et al.
JAMA Network Open|September 19, 2019
Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint InhibitorsDavid Hsiehchen, Mary K Watters, Rong Lu, et al.
Molecular Cancer Therapeutics|June 5, 2013
BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancerBercin Kutluk Cenik, Katherine T Ostapoff, David E Gerber, et al.
Pageof 29

Showing results (61-70 of 288) with videos related to

Sort By:
Pageof 29
Clinical Lung Cancer|April 20, 2012
Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical centerJeffrey T Yorio, Jingsheng Yan, Yang Xie, et al.
Clinical Lung Cancer|December 31, 2018
Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesElizabeth McGehee, David E Gerber, Joan Reisch, et al.
Translational Lung Cancer Research|September 12, 2022
Circulating mitochondrial DNA as a biomarker for lung cancer screeningMitchell S von Itzstein, David E Gerber, John D Minna
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Impact of NCI-mandated scientific review on protocol development and contentNing Ning, Jingsheng Yan, Xian-Jin Xie, et al.
Journal of Radiotherapy in Practice|September 28, 2011
Intracranial hemorrhage during GliaSite RTS manipulation in an anticoagulated patientDavid E Gerber, Stuart A Grossman, Timothy A Chan, et al.
Plos One|January 4, 2013
How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experienceEvelyn O Taiwo, Jeffrey T Yorio, Jingsheng Yan, et al.
JAMA Oncology|June 5, 2016
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment OptionsSaad A Khan, Sandi L Pruitt, Lei Xuan, et al.
JTO Clinical and Research Reports|March 17, 2022
Systemic and Intracranial Efficacy of Osimertinib in <i>EGFR</i> L747P-Mutant NSCLC: Case ReportDavid E Gerber, Melissa Mayer, Jeffrey Gagan, et al.
JAMA Network Open|September 19, 2019
Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint InhibitorsDavid Hsiehchen, Mary K Watters, Rong Lu, et al.
Molecular Cancer Therapeutics|June 5, 2013
BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancerBercin Kutluk Cenik, Katherine T Ostapoff, David E Gerber, et al.
Pageof 29